Positron emission tomography imaging in nonmalignant thoracic disorders

https://doi.org/10.1053/snuc.2002.127291Get rights and content

The role of the fluorodeoxyglucose (FDG) technique positron emission tomography (PET) is well established in the management of patients with lung cancer. Increasingly, it is becoming evident that FDG-PET can be effectively employed to diagnose a variety of benign pulmonary disorders. Knowledge of such applications further expands the domain of this powerful modality and further improves the ability to differentiate benign from malignant diseases of the chest. We describe pertinent technical factors that substantially contribute to optimal imaging of the thoracic structures. Particularly, the complementary role of attenuation correction (AC) to that of non-AC images is emphasized. We further outline the need for and the state of the art for co-registration of PET and anatomic images for diagnostic and therapeutic purposes. We then review patterns of physiologic uptake of FDG in thoracic structures, including the lung, the heart, the aorta and large arteries, esophagus, thymus, trachea, thoracic muscles, bone marrow, and joints and alterations following radiation therapy to the thorax. A great deal of information is provided with regard to differentiating benign from malignant nodules and in particular, we emphasize the role of dual time point imaging and partial volume correction for accurate assessment of such lesions. Following a brief review of the diagnostic issues related to the assessment of mediastinal adenopathies, the role of FDG-PET imaging in environment-induced lung diseases, including pneumoconiosis, smoking, and asthma are described. A large body of information is provided about the role of this technology in the management of patients with suspected infection and inflammation of the lungs such as acquired immunodeficiency syndrome, fever of unknown origin, sarcoidosis, chronic granulomatous disease and monitoring the disease process and response to therapy. Finally, the value of FDG-PET in differentiating benign from malignant diseases of the pleura including asbestosis-related disorders is described at the conclusion of this comprehensive review.

References (242)

  • Bar-ShalomR et al.

    PET imaging in oncology

  • OzsahinH et al.

    Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B

    Blood

    (1998)
  • EngelH et al.

    Whole-body PET: Physiological and artifactual fluorodeoxyglucose accumulations

    J Nucl Med

    (1996)
  • BakheetS et al.

    18-FDG uptake due to benign pathology

  • CookG et al.

    Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine

    Eur J Nucl Med

    (1999)
  • StraussL

    Fluorine-18 deoxyglucose and false-positive results: A major problem in the diagnostics of oncological patients

    Eur J Nucl Med

    (1996)
  • ShreveP et al.

    Pitfalls in oncologic diagnosis with FDG PET imaging: Physiologic and benign variants

    Radiographics

    (1999)
  • WahlR

    To AC or not to AC: That is the question

    J Nucl Med

    (1999)
  • ZasadnyK et al.

    Untreated lung cancer: Quantification of systematic distortion of tumor size and shape on non-attenuation corrected 2-[fluorine-18]fluoro-2-deoxy-d-glucose PET scans

    Radiology

    (1996)
  • BengelF et al.

    Whole-body positron emission tomography in clinical oncology: Comparison between attenuation corrected and uncorrected images

    Eur J Nucl Med

    (1997)
  • ImranM et al.

    Lesion-to-background ratio in nonattenuation-corrected whole-body FDG PET images

    J Nucl Med

    (1998)
  • LonneuxM et al.

    Attenuation correction in whole-body FDG oncological studies: The role of statistical reconstruction

    Eur J Nucl Med

    (1999)
  • KotzerkeJ et al.

    Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma

    Eur J Nucl Med

    (1999)
  • BleckmannC et al.

    Effect of attenuation correction on lesion detectability in FDG PET of breast cancer

    J Nucl Med

    (1999)
  • HustinxR et al.

    Impact of attenuation correction on the accuracy of FDG-PET in patients with abdominal tumors: A free-response ROC analysis

    Eur J Nucl Med

    (2000)
  • ChanW et al.

    Coincidence detection FDG PET in the management of oncological patients: Attenuation correction versus non-attenuation correction

    Nucl Med Commun

    (2001)
  • BedigianM et al.

    Whole-body positron emission tomography for oncology imaging using singles transmission scanning with segmentation and ordered subsets-expectation maximization (OS-EM) reconstruction

    Eur J Nucl Med

    (1998)
  • CarsonR et al.

    A method for postinjection PET transmission measurements with a rotating source

    J Nucl Med

    (1988)
  • KarpJ et al.

    Singles transmission in volume-imaging PET with a 137Cs source

    Phys Med Biol

    (1995)
  • SmithR et al.

    Singles transmission scans performed postinjection for quantitative whole body PET imaging

    IEEE Trans Nucl Sci

    (1997)
  • MeikleS et al.

    Simultaneous emission and transmission (SET) scanning in neurological PET studies

    J Comput Assist Tomogr

    (1997)
  • HudsonH et al.

    Accelerated image reconstruction using ordered subsets of projection data

    IEEE Trans Med Imag

    (1994)
  • RiddellC et al.

    Noise reduction in oncology FDG PET images by iterative reconstruction: A quantitative assessment

    J Nucl Med

    (2001)
  • BenardF et al.

    Clinical evaluation of processing techniques for attenuation correction with 137Cs in whole body PET imaging

    J Nucl Med

    (1999)
  • PaulA et al.

    Effects of iterative reconstruction on image contrast and lesion detection in gamma camera coincidence imaging in lung and breast cancers

    Nucl Med Commun

    (2002)
  • ChoiY et al.

    Factors affecting myocardial 2-[F-18]fluoro-2-deoxy-d-glucose uptake in positron emission tomography studies of normal humans

    Eur J Nucl Med

    (1993)
  • DuarteP et al.

    The association between chronic obstructive pulmonary disease and right ventricle uptake in whole body PET scans

  • YunM et al.

    F-18 FDG uptake in the large arteries: A new observation

    Clin Nucl Med

    (2001)
  • LedermanR et al.

    Detection of atherosclerosis using novel positron-sensitive probe and 18-fluorodeoxyglucose (FDG)

    Nucl Med Commun

    (2001)
  • ZhangZ et al.

    Noninvasive serial monitoring of atherosclerotic progression and regression with FDG-PET in a rabbit model

    J Nucl Med

    (2000)
  • LinE et al.

    FDG uptake in chronic superior vena cava thrombus on positron emission tomographic imaging

    Clin Nucl Med

    (2001)
  • BakheetS et al.

    F-18 FDG uptake in benign esophageal disease

    Clin Nucl Med

    (1999)
  • PatelP et al.

    Normal thymic uptake of FDG on PET imaging

    Clin Nucl Med

    (1996)
  • BrinkI et al.

    Increased metabolic activity in the thymus gland studied with 18F-FDG PET: Age dependency and frequency after chemotherapy

    J Nucl Med

    (2001)
  • AlibazogluH et al.

    Normal thymic uptake of 2-deoxy-2[F-18]fluoro-d-glucose

    Clin Nucl Med

    (1999)
  • BarringtonS et al.

    Skeletal muscle uptake of fluorine-18-FDG: Effect of oral diazepam

    J Nucl Med

    (1996)
  • MinnH et al.

    In vivo effects of insulin on tumor and skeletal muscle glucose metabolism in patients with lymphoma

    Cancer

    (1994)
  • LinE et al.

    Unilateral diaphragmatic crus uptake on FDG positron emission tomographic imaging

    Clin Nucl Med

    (2001)
  • HickesonM et al.

    Demonstration of excessive metabolic activity of thoracic and abdominal muscles on FDG-PET in patients with COPD

    J Nucl Med

    (2002)
  • YaoW et al.

    Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines

    J Nucl Med

    (1995)
  • Cited by (199)

    View all citing articles on Scopus
    View full text